Thursday 16 October, 2025
Objectives: In oncology settings, survival analysis is often conducted to assess the relationship between predictors and efficacy endpoints like progression-free survival…
Read morePoster: Drug/Disease Modelling - Oncology
Adaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology
Thursday 16 October, 2025
Introduction/Objectives: Improving the management of drug resistance is a key challenge in modern oncology. Currently, this problem is approached by…
Read morePredictiveness of the human CYP3A4 transgenic mouse model (Cyp3aXAV) for human drug exposure assessed using a population pharmacokinetic approach
Thursday 16 October, 2025
Introduction: Approximating the human pharmacokinetic (PK) profile as closely as possible in preclinical settings can still be a struggle in…
Read morePhysiologically based pharmacokinetic model to predict chemotherapy exposure in infants through breastfeeding: paclitaxel as an example
Thursday 16 October, 2025
Introduction/Objectives: Little is known about infant safety when breastfed by mothers treated with cytotoxic therapy, with evidence limited to a…
Read moreTarget-mediated drug disposition model of rituximab in patients with diffuse large B-cell lymphoma
Thursday 16 October, 2025
Objectives: Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody which specifically binds to the CD20 antigen expressed on the surface of…
Read morePharmacokinetic, receptor occupancy and pharmacodynamic (PK/RO/PD) modeling of ALX148, a CD47 blocker
Thursday 16 October, 2025
Introduction: ALX148 is a promising anti-CD47 blocker currently undergoing clinical trials, which is designed to enhance the activity of anti-cancer…
Read morePopulation K-PD modelling of PSA kinetics in patients with recurrent prostate cancer.
Thursday 16 October, 2025
Objectives: In patients with recurrent prostate cancer, the addition of docetaxel to androgen-deprivation therapy (ADT) is a standard treatment as…
Read morePopulation Pharmacokinetics Modeling of Monalizumab in Cancer Patients with Longitudinal Patient/Disease Characteristics
Thursday 16 October, 2025
Objectives: Monalizumab is a potentially first-in-class humanized immunoglobulin 4 monoclonal antibody that targets Natural Killer Group 2A (NKG2A), resulting in suppression…
Read moreA Population Pharmacokinetic Model to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients
Thursday 16 October, 2025
Objectives: Lutetium-177 Prostate Specific Membrane Antigen (177Lu-PSMA) is a radiopharmaceutical, currently under investigation in phase 3 trials, that shows promising results…
Read moreOptimizing radionuclide therapy with 177Lu-HA-DOTATATE in patients with neuroendocrine tumors using semi-physiological population PK models
Thursday 16 October, 2025
Objectives Somatostatin receptor (SSTR) expression on neuroendocrine tumor (NET) cells enables targeting of NETs with radiopharmaceuticals for both diagnosis (with…
Read more